TTK Healthcare Limited has announced the appointment of V Sundaresan as Additional Independent Director, following a board meeting held on December 22, 2025. The appointment, recommended by the company's Nomination and Remuneration Committee, is subject to shareholder approval through a special resolution via postal ballot.

Director Appointment Details

The board approved Sundaresan's appointment for a five-year term effective December 22, 2025. The appointment details are outlined below:

Professional Background and Expertise

Sundaresan brings extensive financial leadership experience to the board. He is a commerce graduate from the University of Madras and a Fellow Member of the Institute of Chartered Accountants of India (FCA). His professional journey spans nearly four decades in finance, accounts, audit, and regulatory compliance.

His career highlights include senior positions at prominent organizations:

• General Electric: Held senior financial positions
• Greaves Cotton Co.: Leadership role in finance operations
• BPL Refrigerators: Senior management position
• TTK Group: Nearly three decades of service, retiring as Chief Financial Officer of TTK Prestige Ltd. in October 2020
• Current Role: Partner with M/s Sowmya Sundaresan Co., Chartered Accountants

Key Professional Achievements

Sundaresan's expertise encompasses multiple areas of corporate finance and governance:

• Led enterprise transformation through ERP implementation and data-driven decision-making
• Played key roles in corporate restructuring, including demerger processes and overseas subsidiary establishment
• Established comprehensive audit frameworks and internal controls as an active Risk Management team member
• Developed profit-center accountability models to enhance operational efficiency
• Oversaw organization-wide transition to GST and new Accounting Standards
• Achieved significant improvements in working-capital cycles through analytics and fiscal discipline
• Maintained strong relationships with investors and analysts

Postal Ballot Process and Timeline

The board has approved conducting a postal ballot process through remote e-voting for shareholder approval of the appointment. M/s AK Jain Associates, represented by partners Balu Sridhar and Anil Kumar Jain, has been appointed as scrutinizer for the process.

Complete Calendar of Events

The board meeting commenced at 12:45 PM and concluded at 1:00 PM on December 22, 2025. The company has confirmed that Sundaresan is not disqualified or debarred from holding the office of Director pursuant to Section 164 of the Companies Act, 2013, or by virtue of any SEBI order or other authority. Sundaresan has no relationship with other directors and key managerial personnel of the company.

TTK Healthcare Limited , a prominent player in the healthcare sector, has reported a mixed set of financial results for the second quarter of the fiscal year. The company saw an increase in net profit but faced challenges in terms of EBITDA performance.

Key Financial Highlights

Profit Growth Amidst Challenges

TTK Healthcare demonstrated resilience in its bottom line, reporting a net profit of ₹204.00 crore for Q2, up from ₹172.00 crore in the same period last year, marking an 18.60% increase. This growth in profit is particularly noteworthy given the challenging operating environment.

Revenue Performance

The company's revenue saw a marginal increase, growing to ₹2,000.00 crore from ₹1,980.00 crore year-over-year. This modest 1.00% growth suggests a relatively stable demand for the company's products and services in the market.

EBITDA and Margin Pressure

Despite the growth in revenue and net profit, TTK Healthcare faced significant pressure on its operational efficiency. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined to ₹53.30 crore from ₹82.30 crore in the previous year. This represents a substantial decrease of 35.20%.

More concerning is the compression in the EBITDA margin, which fell to 2.62% from 4.15% in the same quarter last year. This 153 basis points reduction in margin indicates increased operational costs or pricing pressures in the market.

Analysis and Outlook

The divergence between net profit growth and EBITDA decline suggests that TTK Healthcare might have benefited from non-operational factors such as lower tax outgo or exceptional items. The company's ability to maintain profit growth despite margin pressures demonstrates effective cost management in other areas.

However, the significant drop in EBITDA and margin compression warrants attention. It may indicate rising input costs, increased competition, or challenges in pricing power. The management may need to focus on operational efficiency and cost control measures to improve margins in the coming quarters.

As TTK Healthcare navigates through these mixed results, investors and analysts will be keen to see how the company addresses the operational challenges while maintaining its profit growth trajectory in the future quarters.